aripiprazole lauroxil (brand name aristada) is a long-acting injectable atypical antipsychotic that was developed by alkermes. it is an n-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia. aripiprazole lauroxil was approved by the u.s. fda on 5 october 2015.